Meeting
2013 ASCO Annual Meeting
A phase I study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors.
Authors
Hatem Hussein Soliman
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Hatem Hussein Soliman , Susan E. Minton , Hyo S. Han , Roohi Ismail-Khan , Amit Mahipal , William Janssen , Howard Streicher , Nicholas N. Vahanian , Charles J. Link , William Jay Ramsey , Scott J. Antonia , Daniel Sullivan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01042535
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3069)
DOI
10.1200/jco.2013.31.15_suppl.3069
Abstract #
3069
Poster Bd #
17D
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors.
First Author: Hatem Hussein Soliman
Poster
2014 ASCO Annual Meeting
Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma.
First Author: Geoffrey Thomas Gibney
Poster
2023 ASCO Annual Meeting
Phase 1 trial of GD2-SADA:177Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.
First Author: Taofeek K. Owonikoko
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase 1 first-in-human study of XL092 administered alone or in combination with immune checkpoint inhibitors (ICIs) in patients (pts) with inoperable locally advanced or metastatic solid tumors: Description of genitourinary (GU) expansion cohorts.
First Author: Manish Sharma